Sydney, June 12, 2026, 02:12 AEST
- CSL ended the day at A$107.23, gaining 4.16%, after touching an intraday high of A$108.46 on Thursday.
- The move was notable as the S&P/ASX 200 slipped 0.23% to 8,633.20 in a softer session.
- The stock is still trading well under last year’s highs after guidance was cut, leaders switched, and impairment warnings hit investor outlook.
CSL Limited jumped 4.16% to close at A$107.23 on Thursday, snapping back after a rough patch for the healthcare favorite. Shares moved between A$102.15 and A$108.46. About 2.8 million CSL shares traded, topping the usual volume for the name. The move helped lift the ASX healthcare sector, as CSL saw clear buying interest.
ASX slips as oil climbs on Mideast worries
Australian shares edged lower, with the S&P/ASX 200 down 20.10 points or 0.23% to 8,633.20. The All Ordinaries lost 0.23% to finish at 8,836.70. Tension in the Middle East boosted oil, hitting sentiment. Healthcare and energy were firmer. CSL and Pro Medicus were among healthcare gainers. Banks and tech stocks pulled the index lower.
CSL bounced back above its 30-day simple moving average at A$104 on Thursday, The Bull said, but it is still trading under the 50-day mark of A$116.84. Google Finance data shows the 52-week high at A$275.79, with a 52-week low of A$90.00, so the stock is still well off its peak after the recent move.
CSL didn’t release a new operating update on Thursday. Its ASX announcements included a June 9 notice on securities ceasing, a June 5 Appendix 3Y for Carolyn Hewson AO, and a substantial holding change from June 3. The May 11 interim CEO review and financial update was still the last key business statement on the list.
Investors keep coming back to the May update when they look at this stock. CSL put its FY26 revenue outlook at roughly $15.2 billion and guided for NPATA of about $3.1 billion, saying both figures are on a constant-currency base. CSL also warned of around $5 billion more in non-cash, pre-tax impairments expected over FY26 and FY27, with most tied to CSL Vifor intangible assets and under-used property, plant and equipment.
CSL Interim CEO and Managing Director Gordon Naylor said in the update: “Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise.” CSL mentioned it saw clear strengths in plasma collections and influenza vaccines. The company said the revised guidance was due to slower-than-expected financial benefits from its growth plans.
CSL in its review said it expects FY26 revenue to take a $300 million hit as U.S. immunoglobulin channel inventory returns to more normal levels. Another $200 million is seen coming off from lower albumin market values in China, and around $150 million is linked to other issues — such as the Middle East conflict, slower HEMGENIX growth, and iron competition. Despite all that, CSL said it still sees CSL Behring’s revenue rising in the second half. CSL Seqirus is expected to do a bit better than previously flagged in FY26.
The stock’s recent rebound hasn’t undone the bigger reset that started earlier this year. Back in February, Reuters reported CSL’s first-half profit slumped 81%, held back by weaker plasma and vaccine sales, and some one-off charges and impairments. That news hit right after Paul McKenzie exited as CEO and Gordon Naylor took over as interim chief. Reuters said shares tumbled as much as 18% in early trading to an eight-year low.
CSL’s business mix keeps long-term investors interested even after the stock’s selloff. Reuters says CSL focuses on rare and serious diseases, flu vaccines, iron deficiency, and nephrology, operating through CSL Behring, CSL Seqirus, and CSL Vifor. CSL Plasma runs about 325 plasma collection centers in the US, Europe, and China, according to .
CSL’s next key test is its full-year report on August 18. Investors want more detail on plasma margins, inventory levels, China albumin prices, Vifor writedowns, and the hunt for a permanent CEO. CSL shares rallied Thursday, but the bounce came before the earnings concerns behind the earlier selloff were resolved.
